Authors
Xiaoyue Qi, Luoming Zhang, Yaoxin Gao, Shoukui Hu, Yiming Shao, Xiaoyan Jia, Shujuan Zhang, Baodong Ma
Published in
Journal of inflammation research. Volume 19. Pages 609042. Epub Aug 05, 2026.
Abstract
Chrysoeriol (CHR), a naturally derived and non-toxic compound, exhibits potent immunomodulatory and anti-inflammatory activities. This investigation assessed CHR's anti-inflammatory effects and elucidated the mechanism.
For assessing CHR's anti-psoriatic efficacy, imiquimod (IMQ)-induced murine models and LPS-treated HaCaT cells were used. The anti-inflammatory characteristics of CHR were analyzed using the Psoriasis Area Severity Index (PASI), immunohistochemistry, immunofluorescence, and flow cytometry. Furthermore, transcriptome sequencing, immunoblotting, and qRT-PCR were applied to investigate how CHR regulates psoriasis at the molecular level.
In our research, we found that topical CHR administration significantly alleviated IMQ-induced psoriatic manifestations in mice, demonstrating reduced erythema, decreased epidermal thickening, and diminished scaling. Histopathological improvements correlated with lower PASI scores and reduced splenomegaly. CHR restrained excessive activation of Th1/Th17 cells, inhibited keratinocyte hyperproliferation and blunted inflammatory responses, accompanied by decreased phosphorylation of AKT and p65.
CHR exerts robust anti-psoriatic effects by suppressing keratinocyte over-proliferation and restoring Th1/Th17 immune homeostasis. Our data reveal a correlation between CHR intervention and suppressed AKT/NF-κB signaling activation, suggesting CHR may serve as a potential candidate for psoriasis treatment.
PMID:
42572765
Bibliographic data and abstract were imported from PubMed on 10 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0